Myelodysplastic Syndrome Clinical Trial

A Telehealth Advance Care Planning Intervention

Summary

The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.

View Full Description

Full Description

The Serious Illness Care Program (SICP) is an evidence-based intervention to enhance serious illness conversations between physicians and patients with advanced cancer. It consists of the Serious Illness Conversation Guide as well as training and system-level support for clinicians to conduct serious illness conversations. The investigators have previously adapted the SICP to be delivered via telehealth for older adults with myeloid malignancies. In this study, they will conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program compared to an education control.

View Eligibility Criteria

Eligibility Criteria

Inclusion and Exclusion Criteria for Patients

Inclusion Criteria:

Age ≥60 years
A diagnosis of acute myeloid leukemia, myelodysplastic syndrome (MDS), or similar myeloid malignancies (including but not limited to MDS/myeloproliferative neoplasms overlap syndrome, myelofibrosis)
Being managed in the outpatient settings
Able to provide informed consent
English-speaking

Exclusion Criteria:

- None

Inclusion and Exclusion Criteria for Caregivers

Inclusion criteria:

Age ≥18 years
Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters"
Able to provide informed consent
English-speaking

Exclusion criteria

- None

Inclusion and Exclusion Criteria for Oncology Providers

Inclusion criteria:

- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit

Exclusion criteria

- None

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

207

Study ID:

NCT05875805

Recruitment Status:

Not yet recruiting

Sponsor:

University of Rochester

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Rochester
Rochester New York, 14642, United States More Info
Kah Poh Loh, MD
Contact
585-276-4353
[email protected]
Cait F Sharma, MA
Contact
585-276-5432
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

207

Study ID:

NCT05875805

Recruitment Status:

Not yet recruiting

Sponsor:


University of Rochester

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.